Vaccines and Infectious Disease

Patients enrolled in vaccine trials

PBMC processing capabilities and central laboratory support

Average retention rate for vaccine trials

A leader in high-volume vaccine trials and research involving hard-to-reach patients

The majority of the world’s leading Sponsors and CROs have made Meridian a preferred partner for their traditional and next-generation infectious disease programs. This is because Meridian provides a broad North American footprint to support rapid enrollment, even for seasonal studies involving specific cohorts (e.g., seniors, pediatrics, healthy).

As the largest member of the Platinum Research Network, Meridian provides access to more than 40 million patients globally. Meridian also offers a flexible clinical infrastructure to accommodate new technologies and novel approaches.

Meridian principal investigators have had their research published in prestigious industry journals, including Vaccine. These investigators are also sought after by Sponsors and CROs to provide counsel for vaccine-related protocol development.

Across all major and emerging indications, including anti-infectives and immunologics, Meridian supports research programs for drugs, medical devices, diagnostics, and combination products.

Therapeutic experience

  • Anthrax
  • C. difficile
  • Cytomegalovirus (CMV)
  • Dengue fever
  • Ebola
  • H1N1 influenza
  • H5N1 influenza
  • Herpes
  • Human Metapneumovirus (hMPV)
  • Human papillomavirus (HPV)
  • Influenza, including pediatric, geriatric, and off-season
  • Japanese encephalitis
  • Lyme disease
  • Meningococcal
  • Parainfluenza
  • Pediatric meningitis
  • Pediatric influenza
  • Plague
  • Pneumococcal
  • Rabies
  • Respiratory syncytial virus (RSV), including maternal and pediatric
  • SARS-CoV-2 (the coronavirus that causes COVID-19)
  • Smallpox
  • Type 3 (PIV3)/RSV combo
  • West Nile virus
  • Zika virus

Featured vaccine investigators

Brandon Essink, MD, CPI

Brandon Essink, MD, CPI

  • Meridian Medical Director and Principal Investigator since 2003
  • Frequently selected to lead pioneering vaccine research programs
  • Results from clinical studies frequently published in industry journals (recently in Vaccine)
Keith Vrbicky, MD

Keith Vrbicky, MD

  • Meridian Principal Investigator since 2013 in Norfolk, NE
  • Highly-respected physician in his region; frequently published for expertise in maternal vaccination trials
  • Sought after speaker, prominent figure in research for women's health, pediatrics, vaccines
  • Delivered 11,920+ babies

Cumulative vaccine trial enrollment by year

Meridian Vaccine Trial Enrollment

Types of vaccine trials conducted

Meridian Vaccine Trial Indication
Average enrollment for vaccine trials
Therapeutic indications supported
Sites conducting vaccine trials
Principal investigators conducting vaccine trials

Government-funded research experience

In-house QA and superb regulatory track record

First-in-human trial experience

Trial results featured in prestigious publications, including Vaccine

Meridian Clinical Research fleur-de-lis logomark in purple.

Let's Talk About Your Next Vaccine Trial

  • By entering your email address below, you consent to receiving communications from Meridian Clinical Research.
  • Describe your study, research program, or development goals.